ReviewCurrent opinion in rheumatology2011
Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside.
Review in Current opinion in rheumatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review.BioMed research international · 2019Pooled it
- Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis.British journal of clinical pharmacology · 2016Trial
- Plasmablasts as Translational Biomarkers in Autoimmune Diseases: From Cellular Dynamics to Clinical Decision-Making.Current issues in molecular biology · 2026Review
- Lymph Node-Targeted Cyclosporine A Alleviates Myocarditis in Lupus Mice by Inhibiting CD68+ Macrophage-Driven Lymphangiogenesis.Materials today (Kidlington, England) · 2025Article
- Immunotargets and Therapy for Systemic Lupus Erythematosus.ImmunoTargets and therapy · 2025Review
- Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy.Acta neuropathologica communications · 2022Article
- Review
- Here, There, and Anywhere? Arguments for and against the Physical Plasma Cell Survival Niche.Journal of immunology (Baltimore, Md. : 1950) · 2017Review
- A TLR9-dependent checkpoint governs B cell responses to DNA-containing antigens.The Journal of clinical investigation · 2017Article
- Kv1.3 Channel Blockade Modulates the Effector Function of B Cells in Granulomatosis with Polyangiitis.Frontiers in immunology · 2017Article
- Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE.Nature reviews. Rheumatology · 2016Review
- Autoantibodies in SLE: Specificities, Isotypes and Receptors.Antibodies (Basel, Switzerland) · 2016Review
- γ-Secretase directly sheds the survival receptor BCMA from plasma cells.Nature communications · 2015Article
- Impaired receptor editing and heterozygous RAG2 mutation in a patient with systemic lupus erythematosus and erosive arthritis.The Journal of allergy and clinical immunology · 2015Article
- Profile of atacicept and its potential in the treatment of systemic lupus erythematosus.Drug design, development and therapy · 2015Review
- Mechanisms of autoantibody production in systemic lupus erythematosus.Frontiers in immunology · 2015Review
- Genome-wide gene expression profiling reveals unsuspected molecular alterations in pemphigus foliaceus.Immunology · 2014Article
- Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies.Arthritis research & therapy · 2014Article
- Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside.Auto- immunity highlights · 2014Review
- To B or not to B cells-mediate a healthy start to life.Clinical and experimental immunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewBLyS family ligands and receptors are key players in the selection and survival of most mature B lymphocytes. The fundamental role of BLyS in transitional B cell selection, coupled with the relative BLyS-independence of memory B cells and plasma cells, suggests that BLyS may be a useful therapeutic target in strategies directed against preimmune B cell pools. Several agents that target BLyS are in clinical trials now, and we summarize recent results here, with a focus on systemic lupus erythematosus (SLE). RECENT
findingsBelimumab, a human neutralizing anti-BLyS monoclonal antibody, has delivered moderate but positive results in two separate phase III clinical trials for SLE, and was recently recommended for approval by an FDA advisory panel. Additional agents targeting BLyS or other members of this cytokine receptor family are also being tested in clinical trials. SUMMARY: Together, these trials should yield novel therapies for a debilitating and often intractable illness and offer insights that in turn should foster subsequent generations of personalized, targeted therapies for rheumatic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.